The retrieval of rights is based on Daiichi’s decision to conclude a license and co-commercialization agreement with ArQule.
ArQule chief medical officer Brian Schwartz said, "AKT, also known as the serine/threonine kinase PKB, is believed to mediate a number of signal transduction processes and represents a potential therapeutic target for several cancers and other diseases."
ArQule Kinase Inhibitor Platform was leveraged in the development of ARQ 092 selective AKT inhibitor while structure-based drug design methodology is used for optimization.
The AKT signaling pathway usually dysregulated in cancer, plays vital role in cell growth, survival, migration and angiogenesis.